223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

Simple item page
dc.conference.dateSEP 19-OCT 18, 2020
dc.conference.titleESMO Virtual Congress
dc.contributor.authorCarles, J.
dc.contributor.authorAlonso, T.
dc.contributor.authorMellado Gonzalez, B.
dc.contributor.authorMendez Vidal, M. J.
dc.contributor.authorVazquez Estevez, S.
dc.contributor.authorGonzalez del Alba, A.
dc.contributor.authorPiulats, J. M.
dc.contributor.authorBorrega Garcia, P.
dc.contributor.authorGallardo, E.
dc.contributor.authorMorales Barrera, R.
dc.contributor.authorParedes, P.
dc.contributor.authorReig, O.
dc.contributor.authorGarcias de Espana, C.
dc.contributor.authorCollado, R.
dc.contributor.authorBonfill, T.
dc.contributor.authorSuarez, C.
dc.contributor.authorMalfettone, A.
dc.contributor.authorGarde, J.
dc.contributor.authoraffiliation[Carles, J.] Vall dHebron Inst Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Carles, J.] Med Scientia Innovat Res MedSIR, Barcelona, Spain
dc.contributor.authoraffiliation[Alonso, T.] Hosp Univ Ramon & Cajal, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Mellado Gonzalez, B.] Hosp Clin Barcelona, Oncol Serv, Barcelona, Spain
dc.contributor.authoraffiliation[Mellado Gonzalez, B.] Univ Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Mendez Vidal, M. J.] Maimonides Inst Biomed Res Cordoba IMIBIC, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Mendez Vidal, M. J.] Reina Sofia Univ Hosp HURS, Dept Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Vazquez Estevez, S.] Lucus Augusti Univ Hosp, Med Oncol, Lugo, Spain
dc.contributor.authoraffiliation[Gonzalez del Alba, A.] Puerta de Hierro Majadahonda Univ Hosp, Med Oncol, Madrid, Spain
dc.contributor.authoraffiliation[Piulats, J. M.] Catalan Inst Oncol, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Borrega Garcia, P.] San Pedro de Alcantara Hosp, Med Oncol, Caceres, Spain
dc.contributor.authoraffiliation[Gallardo, E.] Parc Tauli Univ Hosp, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Parc Tauli Univ Hosp, Med Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Gallardo, E.] Parc Tauli Inst Res & Innovat I3PT, Barcelona, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Parc Tauli Inst Res & Innovat I3PT, Barcelona, Spain
dc.contributor.authoraffiliation[Gallardo, E.] Barcelona Autonomous Univ, Barcelona, Spain
dc.contributor.authoraffiliation[Bonfill, T.] Barcelona Autonomous Univ, Barcelona, Spain
dc.contributor.authoraffiliation[Morales Barrera, R.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Morales Barrera, R.] Vall dHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Paredes, P.] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Reig, O.] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Paredes, P.] Univ Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Reig, O.] Univ Barcelona, Barcelona, Spain
dc.contributor.authoraffiliation[Garcias de Espana, C.] Son Espases Univ Hosp, Med Oncol, Mallorca, Spain
dc.contributor.authoraffiliation[Collado, R.] Complejo Hosp Caceres, Med Oncol, Caceres, Spain
dc.contributor.authoraffiliation[Suarez, C.] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Suarez, C.] Vall dHebron Inst Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Malfettone, A.] Med Scientia Innovat Res MedSIR, Med Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Garde, J.] Med Scientia Innovat Res MedSIR, Med Dept, Barcelona, Spain
dc.contributor.funderBayer
dc.date.accessioned2025-01-07T13:25:40Z
dc.date.available2025-01-07T13:25:40Z
dc.date.issued2020-09-01
dc.identifier.doi10.1016/j.annonc.2020.08.898
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420408944/pdf
dc.identifier.urihttps://hdl.handle.net/10668/25496
dc.identifier.wosID573469100636
dc.issue.number4
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)
dc.page.numberS525-S526
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.title223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

SAS - Hospital Universitario Reina Sofía
Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía